tert-Butyl 4-allyl-4-formylpiperidine-1-carboxylate

Catalog No.: 
ACPOVK354
CAS No.: 
1793108-52-7
Molecular Formula: 
C14H23NO3
Molecular Weight: 
253.34
tert-Butyl 4-allyl-4-formylpiperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$128.00InquiryInquiry
100mg97%$182.00InquiryInquiry
250mg97%$253.00InquiryInquiry
1g97%$604.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-allyl-4-formylpiperidine-1-carboxylate
IUPAC Nametert-butyl 4-allyl-4-formylpiperidine-1-carboxylate
MDL No.MFCD30294513
Molecular FormulaC14H23NO3
Molecular Weight253.34
SMILESO=C(N1CCC(C=O)(CC=C)CC1)OC(C)(C)C
InChI KeyMZQDMBLLRIEPTM-UHFFFAOYSA-N
SynonymTERT-BUTYL 4-ALLYL-4-FORMYLPIPERIDINE-1-CARBOXYLATE;1-Piperidinecarboxylic acid, 4-formyl-4-(2-propen-1-yl)-, 1,1-dimethylethyl ester
CAS No.1793108-52-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACPOVK354 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTNLC596 route compound structure diagram
    ACTNLC596137076-22-3In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACPOVK354 route product structure diagram
    ACPOVK3541793108-52-7
Inquiry

2. ACPOVK354 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBQDR673 route compound structure diagram
    ACBQDR673236406-37-4In Stock
  2. Then
  3. ACPOVK354 route product structure diagram
    ACPOVK3541793108-52-7
Inquiry

3. ACPOVK354 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACPOVK354 route product structure diagram
    ACPOVK3541793108-52-7
Inquiry

Comments (0)